Top Markets
Coin of the day
Rapid Therapeutic Science Laboratories, Inc. Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc.

RTSL
Classement en actions #42555
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm... Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$883.00
Changement (1 jour)
0.00%
Changement (1 an)
-96.67%
Pays
US
Échange Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Catégorie

Historique du rendement du dividende pour Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Le rendement du dividende (TTM) de Rapid Therapeutic Science Laboratories, Inc. (symbole boursier : RTSL) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Rapid Therapeutic Science Laboratories, Inc. (RTSL) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes